Attacking Cancer’s Key Mechanisms to Treat Metastatic Pancreatic Cancer
A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Testing a New Approach to Treating Advanced Pancreatic Cancer
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Testing a Drug that Works Only in the Tumor Microenvironment
Scientists are trying a new type of drug combination that gets activated only in the unique conditions of the tumor microenvironment.
Testing Treatment Combinations to Make Surgery More Effective
Researchers are looking at losartan and nivolumab combined with standard protocol of chemotherapy and radiation to see either drug or a combination is more effective.
Comparing Treatment Delivery Methods for Locally Advanced Pancreatic Cancer
A clinical trial compares intravenous chemotherapy delivery with intra-arterial chemotherapy to see which is more effective for pancreatic cancer.
A New Drug to Target Cancer Cell Enzymes
In patients with metastatic pancreatic cancer, researchers are comparing FOLFIRINOX, the standard treatment, with FOLFIRINOX plus CPI-613, a new drug…
Targeting Cancer-Associated Wasting With Experimental Immunotherapy
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
